JPRN-UMIN000007787CompletedPhase 3
Randomized phase III trial of surgery followed by mFOLFOX6 as adjuvant chemotherapy versus peri-operative mFOLFOX6 plus cetuximab for KRAS wild type resectable liver metastases of colorectal cancer - EXPERT
Hepato-biliary-pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, The University of Tokyo0 sites500 target enrollmentStarted: April 19, 2012Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Sponsor
- Enrollment
- 500
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •(1) Extrahepatic metastases or history of extrahepatic metastases (2) Metachronous 1 liver metastasis (3) More than 9 liver metastases (4) Prior local therapy for liver metastases (5) Severe comorbidity (6) Synchronous multiple malignancy or metachronous multiple malignancy within 5 years disease free interval (7) Severe infectious disease (8) Women who are unwilling to avoid pregnancy. Women who are pregnant or breastfeeding . Women with a positive pregnancy test (9) Psychological disorder (10) Considered not appropriate for surgery
Investigators
Similar Trials
Not yet recruiting
Phase 3
A phase III randomized study evaluating surgery of residual disease in patients with metastatic gastro-intestinal stromal tumor responding to imatinib mesylateGastro-intestinal stromal tumour (GIST)Cancer - Other cancer typesACTRN12609000681257European Organisation for Research and Treatment of Cancer (EORTC)350
Not yet recruiting
Phase 3
A phase III randomized study evaluating surgery of residual disease in patients with metastatic gastro-intestinal stromal tumor responding to Imatinib mesylate.bowel wall cancer1001799010017998GISTNL-OMON32805European Organisation for Research in Treatment of Cancer (EORTC)60
Active, not recruiting
Not Applicable
A phase III randomized study evaluating surgery of residual disease in patients withmetastatic gastro-intestinal stromal tumor responding to Imatinib mesylate.EUCTR2007-002257-23-GBEuropean Organization for Research and Treatment of Cancer350
Active, not recruiting
Phase 1
A phase III randomized study evaluating surgery of residual disease in patients withmetastatic gastro-intestinal stromal tumor responding to Imatinib mesylate.Metastatic gastro-intestinal stromal tumorMedDRA version: 9.1Level: LLTClassification code 10062427Term: Gastrointestinal stromal tumorEUCTR2007-002257-23-FREuropean Organization for Research and Treatment of Cancer350
Active, not recruiting
Not Applicable
A phase III randomized study evaluating surgery of residual disease in patients withmetastatic gastro-intestinal stromal tumor responding to Imatinib mesylate.EUCTR2007-002257-23-NLEuropean Organization for Research and Treatment of Cancer350